Table 1 Clinicopathological features of patients in the EP group and NEP group before and after propensity score matching
Characteristics | Before matching | After matching | ||||
|---|---|---|---|---|---|---|
EP group (n = 186) | NEP group (n = 440) | p value | EP group (n = 178) | NEP group (n = 175) | p value | |
Age (years) | 80.0 ± 4.1 | 62.6 ± 9.5 |  < 0.001 | 80.2 ± 4.0 | 63.8 ± 9.0 |  < 0.001 |
Sex | Â | Â | 0.206 | Â | Â | 0.473 |
 Male | 127 (68.3) | 323 (73.4) |  | 123 (69.1) | 127 (72.6) |  |
 Female | 59 (31.7) | 117 (26.6) |  | 55 (30.9) | 48 (27.4) |  |
CCI |  |  |  < 0.001 |  |  | 0.002 |
 Low | 65 (34.9) | 243 (55.2) |  | 64 (36.0) | 91 (52.0) |  |
 Moderate/severe | 121 (65.1) | 197 (44.8) |  | 114 (64.0) | 84 (48.0) |  |
 mFI | 0.074 ± 0.068 | 0.046 ± 0.061 |  < 0.001 | 0.073 ± 0.067 | 0.050 ± 0.064 |  < 0.001 |
Number of analyzed lymph nodes | Â | Â | 0.577 | Â | Â | Â |
  < 16 | 8 (4.3) | 21 (4.7) |  | 0 | 0 |  |
 ≥16 | 178 (95.7) | 419 (95.3) |  | 178 | 175 |  |
 Number of positive lymph nodes | 1.75 ± 5.34 | 1.62 ± 5.90 | 0.546 | 1.70 ± 4.80 | 2.13 ± 8.04 | 0.738 |
 Tumor size (mm) | 40.4 ± 25.9 | 38.9 ± 25.6 | 0.470 | 40.5 ± 25.5 | 41.3 ± 26.3 |  |
Depth of tumor invasion | Â | Â | 0.479 | Â | Â | 0.956 |
 T1 | 115 (61.8) | 288 (65.5) |  | 107 (60.1) | 108 (61.7) |  |
 T2 | 26 (14.0) | 49 (11.1) |  | 26 (14.6) | 22 (12.6) |  |
 T3 | 33 (17.7) | 84 (19.1) |  | 33 (18.5) | 34 (19.4) |  |
 T4 | 12 (6.5) | 19 (4.3) |  | 12 (6.8) | 11 (6.3) |  |
Lymph node metastasis | Â | Â | 0.765 | Â | Â | 0.700 |
 Positive | 51 (27.4) | 112 (25.5) |  | 49 (27.5) | 46 (26.3) |  |
 Negative | 135 (72.6) | 328 (74.5) |  | 129 (72.5) | 129 (73.7) |  |
Histologic type | Â | Â | 0.005 | Â | Â | 0.511 |
 Differentiated | 116 (62.4) | 220 (50.0) |  | 111 (62.4) | 115 (65.7) |  |
 Undifferenciated | 70 (37.6) | 220 (50.0) |  | 67 (37.6) | 60 (34.3) |  |
Lymphatic invasion | Â | Â | 0.136 | Â | Â | 0.845 |
 Positive | 110 (59.1) | 231 (52.5) |  | 106 (59.6) | 106 (60.6) |  |
 Negative | 76 (40.9) | 209 (47.5) |  | 72 (40.4) | 69 (39.4) |  |
Venous invasion | Â | Â | 0.004 | Â | Â | 0.973 |
 Positive | 102 (54.8) | 184 (41.8) |  | 100 (56.2) | 98 (56.0) |  |
 Negative | 84 (45.2) | 256 (58.2) |  | 78 (43.8) | 77 (44.0) |  |
Stage of disease | Â | Â | 0.550 | Â | Â | 0.578 |
 I | 124 (66.7) | 308 (70.0) |  | 116 (65.2) | 119 (68.0) |  |
 II | 39 (21.0) | 76 (17.2) |  | 39 (21.9) | 31 (17.7) |  |
 III | 23 (11.3) | 56 (12.8) |  | 23 (12.9) | 25 (14.3) |  |
Type of gastrectomy | Â | Â | 0.508 | Â | Â | 0.951 |
 Distal | 131 (70.4) | 325 (73.9) |  | 125 (70.2) | 125 (71.4) |  |
 Total | 34 (18.3) | 64 (14.5) |  | 34 (19.1) | 33 (18.9) |  |
 Proximal | 21 (11.3) | 51 (11.6) |  | 19 10.7) | 17 (9.7) |  |
Approach | Â | Â | 0.476 | Â | Â | 0.101 |
 Open | 71 (38.2) | 183 (41.6) |  | 67 (37.6) | 82 (46.9) |  |
 Laparo | 115 (61.8) | 257 (58.4) |  | 111 (62.4) | 93 (53.1) |  |
Lymphadectomy | Â | Â | 0.005 | Â | Â | 0.006 |
  < D2 | 136 (73.1) | 293 (66.6) |  | 130 (73.0) | 103 (58.9) |  |
 D2 | 50 (26.9) | 147 (33.4) |  | 48 (27.0) | 72 (41.1) |  |
Adjuvant chemotherapy |  |  |  < 0.001 |  |  |  < 0.001 |
 Present | 12 (6.5) | 84 (19.1) |  | 11 (6.2) | 37 (21.1) |  |
 Absent | 174 (93.5) | 356 (80.9) |  | 167 (93.8) | 138 (78.9) |  |
Death from another disease |  |  |  < 0.001 |  |  | 0.022 |
 Present | 33 (17.7) | 37 (8.4) |  | 31 (17.4) | 16 (9.1) |  |
 Absent | 153 (82.3) | 403 (91.6) |  | 147 (82.6) | 159 (90.9) |  |
Death from primary disease | Â | Â | 0.189 | Â | Â | 0.342 |
 Present | 23 (12.4) | 39 (8.9) |  | 23 (12.9) | 17 (9.7) |  |
 Absent | 163 (87.6) | 401 (91.1) |  | 155 (87.1) | 158 (90.3) |  |
CAR | 0.127 ± 0.342 | 0.066 ± 0.176 |  < 0.001 | 0.121 ± 0.340 | 0.066 ± 0.164 | 0.005 |
NLR | 2.797 ± 1.677 | 2.464 ± 1.597 | 0.002 | 2.778 ± 1.647 | 2.366 ± 1.159 | 0.013 |
PLR | 167.1 ± 87.7 | 160.3 ± 85.3 | 0.327 | 168.2 ± 87.9 | 152.4 ± 66.5 | 0.114 |
PNI | 46.4 ± 5.8 | 50.4 ± 5.6 |  < 0.001 | 46.5 ± 5.8 | 50.1 ± 5.1 |  < 0.001 |